Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

  • STATUS
    Recruiting
  • End date
    Jun 30, 2025
  • participants needed
    40
  • sponsor
    Academic and Community Cancer Research United
Updated on 16 January 2022
platelet count
vasectomy
cancer
monoclonal antibodies
measurable disease
dexamethasone
lenalidomide
neutrophil count
thalidomide
bortezomib
monoclonal protein
immunoglobulin
electrophoresis
carfilzomib
daratumumab
proteasome inhibitor
ixazomib
pomalidomide
immunomodulatory imide drug

Summary

This phase II trial studies how well daratumumab, pomalidomide, and dexamethasone work in treating patients with multiple myeloma that has come back (relapsed). Immunotherapy with daratumumab may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as pomalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving daratumumab with dexamethasone and pomalidomide may work bettering in treating patient compared to dexamethasone and pomalidomide alone.

Description

PRIMARY OBJECTIVE:

I. To determine the overall response rate (partial response [PR], very good partial response [VGPR], complete response [CR], or stringent complete response [sCR]) of daratumumab retreatment in combination with pomalidomide and dexamethasone (DPd) in patients with relapsed refractory multiple myeloma.

SECONDARY OBJECTIVES:

I. To assess progression free survival and overall survival associated with retreatment with daratumumab in combination with pomalidomide and dexamethasone (DPd) in patients with relapsed and refractory multiple myeloma.

II. To determine the toxicities associated with retreatment with daratumumab in combination with pomalidomide and dexamethasone (DPd).

OUTLINE

Patients receive pomalidomide orally (PO) once daily (QD) on days 1-21 and daratumumab intravenously (IV) on days 1, 8, 15, and 22 of cycles 1-2, days 1-15 of cycles 3-6, and day 1 of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8, 15, and 22 of cycles 1-12. Cycles every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for every 3 months until subsequent treatment or progressive disease, then every 6 months for up to 3 years.

Details
Condition Recurrent Plasma Cell Myeloma
Treatment Pomalidomide, Dexamethasone, Daratumumab
Clinical Study IdentifierNCT03841565
SponsorAcademic and Community Cancer Research United
Last Modified on16 January 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Calculated creatinine clearance (using Cockcroft-Gault equation) >= 30 mL/min (obtained =< 14 days prior to registration)
Absolute neutrophil count (ANC) >= 1000/mm^3 (obtained =< 14 days prior to registration)
Untransfused platelet count >= 75,000/mm^3 (obtained =< 14 days prior to registration)
Hemoglobin >= 8.0 g/dL (obtained =< 14 days prior to registration)
Total bilirubin =< 1.5 x upper limit of normal (ULN) (except for patients with Gilbert's syndrome) (obtained =< 14 days prior to registration)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (obtained =< 14 days prior to registration)
Measurable disease of multiple myeloma as defined by at least ONE of the following
Serum monoclonal protein >= 1.0 g/dL
>= 200 mg of monoclonal protein in the urine on 24 hour electrophoresis
Serum immunoglobulin free light chain >= 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio
Bone marrow >= 30% plasma cells
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
Relapsed multiple myeloma (MM) requiring treatment who have previously received a daratumumab alone or in a daratumumab containing combination and
Had at least a partial response to therapy, and had disease progression on or within 60 days of discontinuation
At least 3 months should have elapsed since last exposure to daratumumab
Patients must have been previously exposed to both a proteasome inhibitor and an immunomodulatory imide drug (IMiD)
Examples of proteasome inhibitors
Bortezomib, carfilzomib, ixazomib, marizomib, oprozomib
Examples of IMiD's
Thalidomide, lenalidomide, pomalidomide
Negative pregnancy test done =< 7 days prior to registration, for women of
childbearing potential only
Willing to follow strict birth control measures
Female patients: If they are of childbearing potential, agree to one of the
following
Practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug, AND must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR
Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)
Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, OR
Male patients: even if surgically sterilized (i.e., status post-vasectomy), must
Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)
agree to one of the following
Willing to provide bone marrow and blood samples for planned research
Willing to follow the requirements of the Pomalyst Risk Evaluation and Mitigation
Strategy (REMS) program

Exclusion Criteria

Refractory to pomalidomide
Concurrent amyloid light chain (AL) amyloidosis with organ involvement
Diagnosed or treated for another malignancy =< 2 years prior to registration or previously diagnosed with another malignancy and have any evidence of residual disease. NOTE: Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
Any of the following because this study involves an investigational agent, whose genotoxic, mutagenic and teratogenic effects, on the developing fetus and newborn are
unknown
Pregnant women
Nursing women
Men or women of childbearing potential who are unwilling to employ adequate contraception
Major surgery =< 14 days prior to registration
Evidence of current uncontrolled cardiovascular conditions, including hypertension, cardiac arrhythmias, congestive heart failure, unstable angina, or myocardial infarction =< 6 months. Note: Prior to entry, any electrocardiogram (ECG) abnormality at screening must be documented by the investigator as not medically relevant
Known human immunodeficiency virus (HIV) positive
Other concurrent chemotherapy, or any ancillary therapy considered investigational
NOTE: Bisphosphonates are considered to be supportive care rather than
Known hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection
therapy, and are thus allowed while on protocol treatment
Seropositive for human immunodeficiency virus (HIV)
Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Subjects with resolved infection (i.e., subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR
Seropositive for hepatitis C (except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy)
Known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or investigator's brochure) or known sensitivity to mammalian-derived products
Known chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal
Known moderate or severe persistent asthma within the past 2 years or currently has uncontrolled asthma of any classification
Total bilirubin =< 1.5 x ULN (except for patients with Gilbert's syndrome)
Any serious medical or psychiatric illness that could, in the investigator's opinion
potentially interfere with the completion of treatment according to this
protocol
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note